

General Health Assessment with PROMIS Germany by Charité

Munich, September 06, 2021 - XO Life today announces the release of the General Health Assessment (GHA) on the real-world evidence platform medwatcher.io, which allows every patient to record their current health status. In cooperation with one of the leading research institutes for Patient-Reported Outcome Measures in Europe, the PROMIS Germany of the Charité, every patient now has the possibility to track his current health status according to eight different dimensions, such as physical and mental functioning, in connection with the medication he has taken. The data collected is intended to provide insights into the course of treatment according to various patient-relevant endpoints such as quality of life and tolerability compared to other patients. The collection of GHA data is based on a scientifically validated questionnaire methodology, which is also used in registration studies.

With the implementation of the GHA on the real-world evidence platform, XO Life together with PROMIS Germany sets a standard in the systematic collection of patient experiences, which provides an important data basis for more targeted R&D and the precision medicine of tomorrow. In collaboration with the PROMIS Institute, additional indications are continuously rolled out on the real-world evidence platform.

About XO Life

XO Life is a medtech company based in Berlin and Munich and aims to build the leading real-world evidence platform for patient insights for all medications and therapies.

For this purpose, XO Life cooperates with one of the leading research institute for Patient-Centered Research, PROMIS Germany of Charité, to collect patient experiences in a standardized and systematic way. The data can then be used by the life science industry and medical professions to better understand patients and their treatment courses and successes, and to improve individual treatment offerings.

With the innovative patient insights platform, XO Life also offers a corresponding software solution for user-friendly, digital and efficient drug and treatment monitoring of patients, which can be offered by pharma, medical device and cosmetic manufacturers as well as clinics.

Currently, XO Life is offering a public crowdfunding campaign together with the Aescuvest investment platform specialized in digital health companies: <https://projekte.aescuvest.de/>

Contact

XO Life GmbH

Agnes-Pockels-Bogen 1
80992 München
089 21547481

Dr. Friderike Bruchmann | CEO
friderike.bruchmann@xo-life.com

Niklas Mamuzic | Marketing and Public Relations
niklas.mamuzic@xo-life.com